Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD.
作者信息
Ramakrishnan Madhuri, Coyne Daniel W
机构信息
Division of Nephrology, Department of Medicine, Washington University, St. Louis, MO.
出版信息
Kidney Med. 2020 Jul 2;2(4):385-387. doi: 10.1016/j.xkme.2020.06.003. eCollection 2020 Jul-Aug.
Abstract
摘要
相似文献
1
Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD.在慢性肾脏病患者中测试维生素D类似物对血管钙化的影响
Kidney Med. 2020 Jul 2;2(4):385-387. doi: 10.1016/j.xkme.2020.06.003. eCollection 2020 Jul-Aug.
2
Role of Vitamin D in Uremic Vascular Calcification.维生素D在尿毒症血管钙化中的作用。
Biomed Res Int. 2017;2017:2803579. doi: 10.1155/2017/2803579. Epub 2017 Feb 12.
3
Vitamin D and vascular calcification in chronic kidney disease.维生素 D 与慢性肾脏病中的血管钙化。
Bone. 2009 Jul;45 Suppl 1:S26-9. doi: 10.1016/j.bone.2009.01.011. Epub 2009 Jan 23.
4
Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol.维生素D类似物与3、4期慢性肾脏病患者冠状动脉钙化：骨化三醇与帕立骨化醇的随机对照试验
Kidney Med. 2020 Jun 17;2(4):450-458. doi: 10.1016/j.xkme.2020.05.009. eCollection 2020 Jul-Aug.
5
Vitamin D affects survival independently of vascular calcification in chronic kidney disease.维生素D对慢性肾病患者生存的影响独立于血管钙化。
Clin J Am Soc Nephrol. 2009 Jun;4(6):1128-35. doi: 10.2215/CJN.00260109. Epub 2009 May 14.
6
Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism.骨化三醇加速血管钙化，而与慢性肾脏病伴高磷血症和继发甲状旁腺功能亢进症大鼠模型中的维生素 K 状态无关。
J Pharmacol Exp Ther. 2018 Sep;366(3):433-445. doi: 10.1124/jpet.117.247270. Epub 2018 Jun 14.
7
Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease.维生素 K 缺乏：血管钙化发病机制中的一个新出现的因素，也是晚期肾脏疾病治疗的医源性后果。
Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F618-F623. doi: 10.1152/ajprenal.00278.2020. Epub 2020 Aug 24.
8
Vitamin D Receptor From VSMCs Regulates Vascular Calcification During CKD: A Potential Role for miR-145a.维生素 D 受体（VSMCs）调节 CKD 时的血管钙化：miR-145a 的潜在作用。
Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1533-1548. doi: 10.1161/ATVBAHA.122.318834. Epub 2023 Jun 29.
9
The dualistic role of vitamin D in vascular calcifications.维生素 D 在血管钙化中的双重作用。
Kidney Int. 2011 Apr;79(7):708-14. doi: 10.1038/ki.2010.432. Epub 2010 Oct 20.
10
Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.探讨降低尿酸对血管钙化和 CKD-MBD 标志物的影响：一项随机临床试验的事后分析。
PLoS One. 2018 Oct 24;13(10):e0205831. doi: 10.1371/journal.pone.0205831. eCollection 2018.
本文引用的文献
1
Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol.维生素D类似物与3、4期慢性肾脏病患者冠状动脉钙化：骨化三醇与帕立骨化醇的随机对照试验
Kidney Med. 2020 Jun 17;2(4):450-458. doi: 10.1016/j.xkme.2020.05.009. eCollection 2020 Jul-Aug.
2
Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis.慢性肾脏病患者冠状动脉钙化的患病率及其与死亡率、心血管事件的关系：系统评价和荟萃分析。
Ren Fail. 2019 Nov;41(1):244-256. doi: 10.1080/0886022X.2019.1595646.
3
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 2017慢性肾脏病-矿物质和骨异常（CKD-MBD）诊断、评估、预防及治疗临床实践指南更新
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. Epub 2017 Jun 21.
4
Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial.胆钙化醇、骨化三醇与 CKD 患者血管功能：一项随机、双盲试验。
Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1438-1446. doi: 10.2215/CJN.01870217. Epub 2017 Aug 7.
5
Paricalcitol and endothelial function in chronic kidney disease trial.帕立骨化醇和慢性肾脏病试验中的内皮功能。
Hypertension. 2014 Nov;64(5):1005-11. doi: 10.1161/HYPERTENSIONAHA.114.03748. Epub 2014 Aug 4.
6
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.帕立骨化醇与骨化三醇治疗3-4期慢性肾脏病继发性甲状旁腺功能亢进的随机多中心试验。
Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/CJN.10661013. Epub 2014 Jun 26.
7
Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.帕立骨化醇下调尿毒症大鼠心肌肾素 - 血管紧张素和成纤维细胞生长因子的表达并减轻心脏肥大。
Am J Hypertens. 2014 May;27(5):720-6. doi: 10.1093/ajh/hpt177. Epub 2013 Sep 26.
8
Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.帕立骨化醇对 CKD 患者左心室质量和功能的影响--OPERA 试验。
J Am Soc Nephrol. 2014 Jan;25(1):175-86. doi: 10.1681/ASN.2013010103. Epub 2013 Sep 19.
9
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.维生素 D 可降低左心室肥厚伴慢性肾脏病患者的左心房容积。
Am Heart J. 2012 Dec;164(6):902-9.e2. doi: 10.1016/j.ahj.2012.09.018. Epub 2012 Oct 29.
10
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.维生素 D 治疗与慢性肾脏病患者的心脏结构和功能：PRIMO 随机对照试验。
JAMA. 2012 Feb 15;307(7):674-84. doi: 10.1001/jama.2012.120.
Zotero 插件